This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Gábor Egri Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Egri, G. Articles by Orosz, I. Search for Related Content PubMed PubMed Citation Articles by Egri, G. Articles by Orosz, I. Related Collections Lung - cancer Lung - basic science

Elevated anti-cholesterol antibody levels in the sera of non-small cell lung cancer patients

^a Thoracic Surgical Department, Bajcsy-Zsilinszky Hospital, 89-91 Maglódi Str, 1106 Budapest, Hungary
^b First Department of Paediatrics, Semmelweis University, 53 Bókay Str, 1083 Budapest, Hungary

*Corresponding author. Tel./fax: +36-13190962.

E-mail address: egriga{at}gmail.hu (G. Egri).

There have been no published data yet on the serum level of antibodies against cholesterol (anti-cholesterol antibodies) in oncological patients. We decided to examine these levels in the sera of non-small cell lung cancer (NSCLC) patients. Measurements were performed by ELISA technique in the sera of 44 NSCLC patients and the results were compared to the anti-cholesterol antibody levels of 34 non-tumorous control subjects. Serum anti-cholesterol antibody levels were found to be significantly higher in NSCLC patients than in non-tumorous controls (40.35 arbitrary units/ml (AU/ml) versus 26.00 AU/ml, P=0.0003). The elevated anti-cholesterol antibody values were observable at different percentile values as well (25 percentile: 27.01 AU/ml in NSCLC patients, versus 17.33 AU/ml in controls; 75 percentile: 60.90 AU/ml in NSCLC patients versus 32.90 AU/ml in controls). These results suggest that anti-cholesterol antibodies might be applicable for the serodiagnosis of NSCLC. We emphasize the need for the collection of more data on anti-cholesterol antibody levels in NSCLC patients and in patients with different other malignant tumours in order to investigate the possible benefit anti-cholesterol antibodies might offer in clinical work.

Key Words: Anti-cholesterol antibodies; Non-small cell lung cancer; Serum tumour markers